Cancer Research Targets  Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guidoboni, M.
Right arrow Articles by Dolcetti, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guidoboni, M.
Right arrow Articles by Dolcetti, R.
[Cancer Research 65, 587-595, January 15, 2005]
© 2005 American Association for Cancer Research


Experimental Therapeutics, Molecular Targets, and Chemical Biology

Retinoic Acid Inhibits the Proliferative Response Induced by CD40 Activation and Interleukin-4 in Mantle Cell Lymphoma

Massimo Guidoboni1, Paola Zancai1, Roberta Cariati1, Silvana Rizzo1, Jessica Dal Col1, Alessandro Pavan1, Annunziata Gloghini3, Michele Spina4, Antonio Cuneo5, Fabrizio Pomponi6, Antonio Bononi7, Claudio Doglioni8, Roberta Maestro2, Antonino Carbone3, Mauro Boiocchi2 and Riccardo Dolcetti1

1 Immunovirology and Biotherapy Unit and 2 Division of Experimental Oncology 1, Department of Pre-clinical and Epidemiological Research; 3 Division of Pathology; and 4 Division of Medical Oncology A, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano, Italy; 5 Hematology Section, Department of Biomedical Sciences and Advanced Therapies, University of Ferrara; 6 Division of Hematology, San Bortolo Hospital, Vicenza, Italy; 7 Division of Medical Oncology, General Hospital, Rovigo, Italy; and 8 Division of Pathology, San Raffaele H Scientific Institute, Milan, Italy

Requests for reprints: Riccardo Dolcetti, Immunovirology and Biotherapy Unit, Department of Pre-clinical and Epidemiological Research, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Via Pedemontana Occidentale 12, 33081, Aviano (PN), Italy. Phone: 39-434-659-660, ext. 435; Fax: 39-434-659-659; E-mail: rdolcetti{at}cro.it.

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin's lymphoma with poor response to therapy and unfavorable prognosis. Here, we show that retinoic acid (RA) isomers significantly inhibit the proliferation of both primary MCL cultures (n = 7) and established cell lines (Granta 519 and SP-53) as shown by [3H]thymidine uptake and carboxyfluorescein diacetate succinimidyl ester labeling coupled with cyclin D1 staining. RA induces cell accumulation in G0-G1 together with a marked up-regulation of p27Kip1 by inhibiting ubiquitination and proteasome-dependent degradation of the protein. The p21Cip1 inhibitor was also up-regulated by RA in Granta 519 cells, whereas the expression of cyclin D1 is unaffected. Most of RA-induced p27Kip1 was bound to cyclin D1/cyclin-dependent kinase 4 complexes, probably contributing to the decreased cyclin-dependent kinase 4 kinase activity and pRb hypophosphorylation observed in RA-treated cells. Experiments with receptor-selective ligands indicate that RA receptor {alpha} cooperates with retinoid X receptors in mediating RA-dependent MCL cell growth inhibition. Notably, RA isomers, and particularly 9-cis-RA, also inhibited the growth-promoting effect induced in primary MCL cells by CD40 activation alone or in combination with interleukin-4. Immunohistochemical analysis showed that significant numbers of CD40L-expressing lymphoid cells are present in lymph node biopsies of MCL patients. These results therefore further strengthen the possibility that triggering of CD40 by infiltrating CD40L+ cells may continuously promote the growth of MCL cells in vivo. On these grounds, our findings that RA inhibits basal MCL proliferation as well as MCL growth-promoting effects exerted by microenvironmental factors make these compounds highly attractive in terms of potential clinical efficacy in this setting.

Key Words: mantle cell lymphoma • retinoic acid, RAR/RXR • CD40 • p27Kip1




This article has been cited by other articles:


Home page
BloodHome page
W. J. Chng, E. D. Remstein, R. Fonseca, P. L. Bergsagel, J. A. Vrana, P. J. Kurtin, and A. Dogan
Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications
Blood, January 15, 2009; 113(3): 635 - 645.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Dal Col, P. Zancai, L. Terrin, M. Guidoboni, M. Ponzoni, A. Pavan, M. Spina, S. Bergamin, S. Rizzo, U. Tirelli, et al.
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
Blood, May 15, 2008; 111(10): 5142 - 5151.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
Y. Ishimaru, T. Komatsu, M. Kasahara, Y. Katoh-Fukui, H. Ogawa, Y. Toyama, M. Maekawa, K. Toshimori, R. A. S. Chandraratna, K.-i. Morohashi, et al.
Mechanism of asymmetric ovarian development in chick embryos
Development, February 15, 2008; 135(4): 677 - 685.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M.-S. Lee, S.-A. Yoo, C.-S. Cho, P.-G. Suh, W.-U. Kim, and S. H. Ryu
Serum Amyloid A Binding to Formyl Peptide Receptor-Like 1 Induces Synovial Hyperplasia and Angiogenesis
J. Immunol., October 15, 2006; 177(8): 5585 - 5594.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Q. Chen and A. C. Ross
Inaugural Article: Vitamin A and immune function: Retinoic acid modulates population dynamics in antigen receptor and CD38-stimulated splenic B cells
PNAS, October 4, 2005; 102(40): 14142 - 14149.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.